Welcome to our dedicated page for Co-Diagnostics SEC filings (Ticker: CODX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking the rollout of the Co-Dx PCR platform or gauging demand for Co-Primers™ reagents means decoding financial signals buried deep in SEC documents. If you have ever searched for “Co-Diagnostics quarterly earnings report 10-Q filing” or “Co-Diagnostics 8-K material events explained,” you know the challenge: dense biotech language, assay-validation footnotes and tables that stretch for pages.
Stock Titan’s AI turns that complexity into clarity. Our engine parses each sentence of the latest Co-Diagnostics annual report 10-K simplified, highlights revenue tied to infectious-disease kits and links regulatory milestones to real numbers. It also streams Co-Diagnostics Form 4 insider transactions real-time, so you can follow Co-Diagnostics insider trading Form 4 transactions and monitor executive stock transactions Form 4 without refreshing EDGAR. Prefer the quick path? Click “AI Summary” to get Co-Diagnostics SEC filings explained simply in under a minute, including focused sections on the proxy statement executive compensation and pending product clearances.
Every filing type is one click away:
- 10-Q earnings report filing analysis with segment breakouts
- Instant alerts on Co-Diagnostics 8-K material events
- Understanding Co-Diagnostics SEC documents with AI through plain-language highlights
- Historical archives for research or compliance reviews
Whether you’re comparing R&D spend quarter over quarter, mapping royalty streams, or timing trades around FDA decisions, our real-time updates and expert commentary keep you ahead. Save hours of manual reading and focus on what matters most inside every Co-Diagnostics filing.
Broadcom Inc. (NASDAQ: AVGO) filed a Form 8-K dated 11 July 2025 detailing two related capital-structure actions.
1. Termination of Existing Credit Agreement (Item 1.02)
• The company repaid in full and terminated its August 15 2023 credit agreement, which originally provided a $30.4 billion term-loan facility.
• Immediately before repayment, $6.0 billion of principal was outstanding; the facility would have matured in 2028 and bore interest at a floating rate (alternate base rate or Term SOFR plus a ratings-based margin).
2. New Senior-Notes Offering (Item 8.01)
• On 7 July 2025 Broadcom executed an underwriting agreement to issue $6.0 billion of unsecured senior notes:
- $1.75 billion 4.600% notes due 2030
- $1.75 billion 4.900% notes due 2032
- $2.50 billion 5.200% notes due 2035
• Net proceeds, together with cash on hand, were used to retire the term-loan facility described above.
Strategic Implications
• The transaction shifts $6 billion of floating-rate bank debt maturing in 2028 to fixed-rate public notes maturing between 2030–2035, extending Broadcom’s maturity ladder and removing variable-rate exposure.
• No financial statements were included; therefore, changes to leverage, coverage, or liquidity ratios are not quantified within this filing.
FAQ
What is the current stock price of Co-Diagnostics (CODX)?
What is the market cap of Co-Diagnostics (CODX)?
What is Co-Diagnostics, Inc.'s core business?
What is Co-Primers™ technology?
What markets does Co-Diagnostics serve?
What are Co-Diagnostics' key products?
How does Co-Diagnostics differentiate itself from competitors?
What is Co-Diagnostics' role in global health initiatives?
What is the Co-Dx PCR platform?
What is Co-Diagnostics' joint venture in India?
How does Co-Diagnostics address regulatory challenges?
What are the future plans for Co-Diagnostics?
